Companies also provide insights into proposed strategic mergerSAN MATEO, Calif., Jan. 29, 2025 (GLOBE NEWSWIRE) -- Vincerx ...

SAN MATEO, Calif. - Vincerx Pharma, Inc. (NASDAQ:VINC), a clinical-stage biopharmaceutical company with a current market capitalization of $2.77 million, and Oqory, Inc. announced promising results ...

The company has already cut its workforce, seen a leadership change and agreed to be acquired. Here's what's next.

Vincerx’s Common Stock to Begin Trading on a Split-adjusted Basis on January 28, 2025SAN MATEO, Calif., Jan. 23, 2025 (GLOBE ...

Vincerx Pharma (VINC) announced that its board of directors approved a 1-for-20 reverse stock split of its issued shares of common stock, which ...

Vincerx Pharma, Inc. (NASDAQ:VINC), a pharmaceutical company, announced today an agreement with H.C. Wainwright & Co., LLC to sell up to $30 million of its common stock in an at-the-market equity ...

Vincerx Pharma, Inc. has announced a proposed merger with Oqory, Inc., a clinical-stage company developing antibody-drug conjugates (ADCs) for various cancer types. After the merger, Oqory's ...

EST Vincerx Pharma (VINC) files $100M mixed securities shelfInvest with Confidence: Follow TipRanks' Top Wall Street Analysts to uncover ...

Vincerx Pharma, Inc. operates as a clinical-stage biopharmaceutical company which develops antibody drugs. It focuses on leveraging its extensive development and oncology expertise to advance new ...

Vincerx Pharma said it had agreed to merge with private biotechnology company Oqory after a review of strategic alternatives. The biotech company said that it would also implement cost-cutting ...